Brinsupri: which tox species, and why?

“repeat-dose toxicology studies conducted in the rat and dog for durations up to 26 weeks and 39 weeks, respectively”

“brensocatib is an effective reversible inhibitor of recombinant dipeptidyl peptidase 1 (DPP1) in humans, mice, rats, and dogs, and confirmed the subsequent inhibition of NSP activities (NE, PR3, CatG) in human samples obtained from subjects treated with clinically relevant doses. The in-vitro data also support the selected test species for safety studies with regard to pharmacologically relevance”

“In the 39-week GLP study in dogs, animals were administered 0 (vehicle), 1, 2, 4 or 8 mg/kg/day brensocatib orally for 39 weeks with a 26-week recovery period.”